Latest News

Aug 2, 2017

Propanc Biopharma Confirms No Treatment Related Findings for PRP in 28-Day Repeat-Dose Toxicity Study

Company Prepares Orphan Drug Designation Application to FDA for Treatment of Ovarian Cancer MELBOURNE, AUSTRALIA -- (Marketwired) -- 08/02/17 -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma"…

View All Press Releases